Skip to main content
ABVX logo

ABVX · Abivax S.A.

Track ABVX — free
$114.39 -2.14 (-1.83%)
Market Cap
$10.17B
Shares
87.25M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$116.52 Open$117.00 Day$116.01–118.00 52W close$72.50–145.31 Avg vol 30d917K Short int6.0M · 6.9% float · 7.8d Short vol54% Last earningsDec 31, 2023 DataOct 2023–Aug 2026

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.2 · calm Equity put/call 0.64
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −2%
below
Price vs 50-day avg −5%
below
RSI (14) 41
neutral
MACD trend Negative
52-week position 60%
mid-range
Momentum
relative strength
Weak
1-month return −2%
trailing
6-month return +3%
trailing
YTD return −14%
this year
Relative strength −9%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $123 › 200d $119 — 50d above 200d
Institutional flow Accumulating
+21% holders QoQ · +95 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.88% of float · ▲ +15.5% MoM · 7.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
307 holders — near 2-yr high, broad support
Squeeze score 71
high risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 85%
annualized · 1-yr
Max drawdown −50%
past year
ATR 4.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−2% Neutral
Price vs 50-day avg
−5% Bearish
RSI (14)
41 Neutral
MACD trend
Negative Bearish
52-week position
60% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $123 › 200d $119 — 50d above 200d
Institutional flow Accumulating
+21% holders QoQ · +95 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.88% of float · ▲ +15.5% MoM · 7.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
307 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $73 Now $117 · 60% Range high $145
vs 200-day avg -2% vs 50-day avg -5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ABVX
Abivax S.A.
this stock
$10.17B -13.6% 6.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
$138.72B +20.7% +46.2% 31.9 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
$83.89B +5.6% +20.8% 20.2 2.3%
ARGX
Argenx SE
$65.12B +24.5% 1.9%
CSLLY
Csl Ltd
$59.92B 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
307
% held
76.3%
Net QoQ
+13.6M sh
Top holder
TCG Crossover Management,…
Held Float
View
Held by Funds
Fund positions
98
View
Short & Settlement
Short Interest Rising
Shares short
6.0M
Days to cover
7.8d
Change
+807.0K sh
View
Short Volume
Short vol %
54%
As of
Aug 26, 2026
Short Total
View
Fails to Deliver
FTD shares
16.0K
Value
$2.0M
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
44.4%
Week of
Jul 20, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Jul 2, 2026
This year
10
View
Proposed Sales
Value
$133.7M
Shares
1.0M
Filed
Jan 8, 2026
View
Earnings & Events
Earnings Calls
Last call
Dec 31, 2023
View
Investor Relations
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
ABVX -3.4% -2.0% +3.4% -6.7% -13.6%
SPY -0.4% +5.0% +12.4% +2.6% +12.3%
vs SPY -3.0% -7.0% -9.1% -9.3% -25.9%
Key facts CIK 1956827 CUSIP 00370M103 13F (30d) 266 filings 266 filers Visit website Investor relations